Human Pappalysin-2(PAPPA2) ELISA kit

Code CSB-EL017436HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
pappalysin 2
Alternative Names
PAPPA 2 ELISA Kit; PAPP E ELISA Kit; PAPP-A2 ELISA Kit; PAPP-E ELISA Kit; PAPP2_HUMAN ELISA Kit; PAPPA2 ELISA Kit; Pappalysin 2 ELISA Kit; Pappalysin-2 ELISA Kit; PLAC3 ELISA Kit; Pregnancy associated plasma protein A2 ELISA Kit; Pregnancy associated plasma protein E1 ELISA Kit; Pregnancy-associated plasma protein A2 ELISA Kit; Pregnancy-associated plasma protein E1 ELISA Kit
Abbreviation
PAPPA2
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, urine, tissue homogenates
Detection Range
2 ng/mL-60 ng/mL
Sensitivity
0.5 ng/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cardiovascular
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<15%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<15%        
Three samples of known concentration were tested in twenty assays to assess.      
               
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human PAPPA2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:1 Average % 90    
Range % 85-98    
1:2 Average % 92    
Range % 88-99    
1:4 Average % 94    
Range % 90-101    
1:8 Average % 94    
Range % 86-102    
Recovery
The recovery of human PAPPA2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
 
Sample Type Average % Recovery Range    
Serum (n=5) 97 92-100    
EDTA plasma (n=4) 95 88-99    
               
               
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
 
ng/ml OD1 OD2 Average Corrected    
60 2.517 2.483 2.500 2.453    
25 1.294 1.328 1.311 1.264    
10 0.614 0.626 0.620 0.573    
4 0.311 0.299 0.305 0.258    
2 0.159 0.156 0.158 0.111    
0 0.046 0.047 0.047      
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human PAPPA2 ELISA Kit was designed for the quantitative measurement of Human PAPPA2 protein in serum, plasma, urine, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 2 ng/mL-60 ng/mL and the sensitivity is 0.5 ng/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Metalloproteinase which specifically cleaves insulin-like growth factor binding protein (IGFBP)-5 at the '163-Ser-|-Lys-164' bond. Shows limited proteolysis toward IGFBP-3.
Gene References into Functions
  1. PAPP-A2 mutation is associated with idiopathic short stature. PMID: 29653372
  2. The findings suggest a possible pathophysiological link between the development of Fetal growth restriction and the expression of PAPPA, PAPPA2 and PLAC-1. PMID: 29532882
  3. Pregnancy associated plasma protein-A (PAPP-A) appears to be a potentially useful biomarker for short-term risk stratification of patients presenting with chest pain of ischemic origin (Review). PMID: 29144175
  4. PAPP-A2 is increased in Hemodialysis patients and interacts with PAPP-A on patients prognosis. PMID: 28854436
  5. This review evaluates the current data concerning PAPP-A2 function, and particularly the effect of PAPP-A2 mutation on growth. PMID: 29238946
  6. These patients provide important insights into the regulation of longitudinal growth in humans, documenting the critical role of PAPP-A2 in releasing IGF-I from its binding proteins. PMID: 26902202
  7. Short-term treatment with progressive doses of rhIGF1 (recombinant human insulin-like growth factor-1) improved growth in two siblings with deficiency of PAPP-A2 (pregnancy-associated plasma protein-A2) [due to a homozygous loss-of-function frameshift mutation in exon 3 of the PAPP-A2 gene (p.D643fs25*)] that resulted in postnatal growth failure due to resulting decrease in IGF1 bioavailability. [CASE REPORT] PMID: 27648969
  8. in situ hybridization (ISH) and immunohistochemistry (IHC) were employed to examine the spatial and temporal expression of PAPPA2 in the human fetomaternal interface. PMID: 27525857
  9. PAPP-A2 is differentially expressed in different trophoblast populations and shows strong down regulation in the mid second trimester in chorionic villous samples. PMID: 26748159
  10. overexpression in Down syndrome from placental mRNA to maternal serum protein PMID: 25154785
  11. The association between this PAPPA2 single nucleotide polymorphism and developmental dysplasia of the hip was evaluated. PMID: 24672801
  12. The upregulation of PAPP-A2 observed in preeclampsia at term occurs early in pregnancy, before the symptoms develop. PMID: 24336677
  13. PAPPA2 may be upregulated in severe pre-eclampsia and, functionally, this may be mediated via increased placental hypoxia known to occur with this pregnancy disorder. PMID: 23484525
  14. The existence of this assay will enable an assessment of the biomarker potential of PAPP-A2 in pre-eclampsia as well as other clinical conditions. PMID: 23804707
  15. Association of a single nucleotide polymorphism in pregnancy-associated plasma protein-A2 with developmental dysplasia of the hip PMID: 22037112
  16. factors previously known to be highly expressed in preeclamptic placentae (PGE2 and TNF-alpha), contribute to the upregulation of PAPPA2. results are consistent with the hypothesis that PAPPA2 is upregulated as a consequence of placental pathology PMID: 21496272
  17. Circulating IGFBP-5 is proteolyzed by PAPP-A2 during pregnancy, resulting in increased IGF bioavailability, which may have important consequences for the development of the fetus and/or the well-being of the mother. PMID: 20103653
  18. Seven placental transcripts characterize HELLP-syndrome. PMID: 18374411
  19. PAPP-A2 in syncytiotrophoblast cells was dramatically increased in pre-eclampsia. Maternal serum concentrations of PAPP-A2 were also significantly elevated in pre-eclampsia as compared with uncomplicated pregnancy. PMID: 18805800
  20. Preeclampsia involves changes in the gene expression of PAPPA2 in placental cytotrophoblasts. PMID: 18818296
  21. PAPPA2 is expressed in the syncytiotrophoblast layer of human placental villi and is also detected in some invasive extravillous trophoblasts in the first trimester PMID: 19474058

Show More

Hide All

Subcellular Location
Secreted.
Protein Families
Peptidase M43B family
Tissue Specificity
Expressed abundantly in placenta, and non-pregnant mammary gland with low expression in the kidney, fetal brain and pancreas.
Database Links

HGNC: 14615

KEGG: hsa:60676

STRING: 9606.ENSP00000356634

UniGene: Hs.187284

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1